Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis.

Annals of Hematology
Maximilian MairDominic Fong

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) as well as the introduction of novel agents (NA) significantly improved survival for patients with multiple myeloma (MM). A total of 150 unselected newly diagnosed MM patients treated at our institution from 1998 to 2017 were retrospectively analyzed. Median age at diagnosis was 69 years (range 33-93 years) with a median follow-up of 48.6 months. The median overall survival (OS) for the entire cohort was 60.7 months (range 0.3-280.1). Patients who received frontline HD-ASCT (p < 0.01) or NA-based first-line treatment (p = 0.043) had a significantly better OS. According to the revised Myeloma Comorbidity Index (R-MCI), patients were defined as fit (36.5%), intermediate-fit (44.5%), or frail (19%) with a significant difference in OS between these categories (p < 0.01). Multivariate analysis revealed R-MCI as an independent prognostic factor for OS (p < 0.01). Presence of subclinical amyloid deposits (A+) was detected in 18 out of 66 patients (27.3%) and significantly correlated with a serum free light chain (sFLC) ratio ≥ 100 (p = 0.01) and bone marrow plasma cell infiltration > 60% (p = 0.04). Furthermore, patients with A+ had significantly worse O...Continue Reading

References

Nov 1, 1965·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·H Puchtler, F Sweat
Sep 26, 1997·The New England Journal of Medicine·R H FalkM Skinner
Apr 12, 2001·Journal of Clinical Epidemiology·R Bender, S Lange
Jan 17, 2003·Mayo Clinic Proceedings·Robert A KylePhilip R Greipp
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Paul FermandUNKNOWN Group Myelome-Autogreffe
Jul 25, 2009·Clinical Reviews in Allergy & Immunology·Anupama BhatM Eric Gershwin
Nov 7, 2009·Annals of Hematology·Fara PetruzzielloBruno Rotoli
Feb 11, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Barbara DeschlerJürgen Finke
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan L WarrenGregory A Abel
Jun 12, 2014·Cancer·Kate J NewberrySrdan Verstovsek
Apr 23, 2015·Hematological Oncology·Ulrich J M MeyFelicitas Hitz
Jun 14, 2016·British Journal of Haematology·Marc S RaabKwee Yong
Jun 23, 2016·British Journal of Haematology·Rajshekhar ChakrabortyShaji K Kumar
Jul 14, 2016·British Journal of Haematology·Kwee YongMichele Cavo
Nov 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MustoUNKNOWN International Myeloma Working Group
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 18, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Firoozeh SahebiNicolaus Kröger
Nov 24, 2018·British Journal of Haematology·Marc S RaabKwee Yong

❮ Previous
Next ❯

Citations

Oct 31, 2020·Cancers·Daniela IannazzoAlessandra Bitto

❮ Previous
Next ❯